Form 4: RenovoRx Grants Stock Options to Chief Clinical Officer

RenovoRx, Inc. has issued 128,550 stock options to its Chief Clinical Officer, Leesa Gentry, as part of a long-term incentive and retention strategy.

Summary

• Chief Clinical Officer Leesa Gentry was granted 128,550 stock options on April 3, 2026.
• The options carry an exercise price of $0.98 per share.
• The grant is split into 66,954 incentive stock options and 61,596 non-qualified stock options.
• Vesting occurs monthly over a four-year period (1/48 per month) which began retroactively on January 1, 2026.
• The options are scheduled to be fully vested by January 1, 2030, and will expire on April 3, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative event, signaling executive stability and long-term clinical focus without immediate impact on market fundamentals.

Positives

• Strong alignment of executive interests with shareholder value through a four-year vesting schedule.
• Retention of key clinical leadership during a critical growth phase for the company.
• The exercise price of $0.98 sets a clear performance baseline for management.

Negatives

• Potential future dilution of 128,550 shares for existing shareholders upon exercise of the options.

Risks

• The options are only exercisable if an effective registration statement is in place, creating a dependency on regulatory compliance.
• The value of the incentive is entirely dependent on the stock price remaining above the $0.98 exercise price.

Future Outlook

The grant indicates a long-term commitment to clinical leadership through 2030, suggesting the company is planning for extended clinical development and regulatory timelines.

Management Comments

• The options will only become exercisable when there is an effective registration statement covering the shares underlying the options.

Industry Context

StockSavvy.ai notes that equity-based compensation is a standard practice in the biotechnology and medical device sectors to preserve cash reserves while incentivizing key personnel during lengthy and capital-intensive clinical trial phases.

Comparison to Industry Standards

• The four-year vesting period with monthly increments is consistent with standard executive compensation packages in the life sciences industry.
• The use of both Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NQSOs) is a common strategy for optimizing tax outcomes for U.S.-based executives.

Corporate Governance

Stakeholder Impact

• Shareholders: Face minor potential dilution over the next four to ten years.
• Management: Increased financial incentive for the Chief Clinical Officer to achieve long-term corporate milestones.

Next Steps

• Monthly vesting of options through January 2030.
• Maintenance of an effective registration statement to allow for future option exercises.

Key Dates

Recommendation

This filing represents a routine executive compensation update. While it confirms management stability, it does not provide new data on clinical progress or financial performance that would warrant a change in investment rating.

Keywords

RenovoRx, RNXT, Stock Options, Executive Compensation, Leesa Gentry, Chief Clinical Officer, Equity Grant, Insider Trading